Global Allergy Conjunctivitis Market Projected to Reach $3.2 Billion by 2028, Driven by Increasing Allergies and Technological Innovations - Long-term Forecast to 2032 - ResearchAndMarkets.com

The global allergy conjunctivitis market is set to grow from $2.4 billion in 2023 to an estimated $3.2 billion in 2028, demonstrating a robust compound annual growth rate (CAGR) of 5.9%.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Friday, April 5, 2024
Information
Tags: 
Health, Optical, Patient, Allergy, Research, Growth, Prevalence, Allergic conjunctivitis, Pollutant, Allergen
Geotags: 
NORTH AMERICA
⚠ generated by AI ↴
Organisation: 
RESEARCH AND MARKETS, RESEARCHANDMARKETS.COM
Summary
Key Points: 
  • The global allergy conjunctivitis market is set to grow from $2.4 billion in 2023 to an estimated $3.2 billion in 2028, demonstrating a robust compound annual growth rate (CAGR) of 5.9%.
  • This growth is fueled by a rise in the global burden of allergies, advancements in personalized medicine, and an expanding elderly population.
  • Innovation in biotechnological research and wider healthcare access in developing regions also contribute to the market's upward trajectory.
  • This noteworthy expansion of the allergy conjunctivitis market reflects a concentrated effort to meet the healthcare needs of those suffering from ocular allergies.


The "Allergy Conjunctivitis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

Market Expansion Driven by Increasing Allergies and Technological Innovations in Treatment

The global allergy conjunctivitis market is set to grow from $2.4 billion in 2023 to an estimated $3.2 billion in 2028, demonstrating a robust compound annual growth rate (CAGR) of 5.9%. This growth is fueled by a rise in the global burden of allergies, advancements in personalized medicine, and an expanding elderly population. Innovation in biotechnological research and wider healthcare access in developing regions also contribute to the market's upward trajectory.

Environmental Factors and Lifestyle Changes Propel Market Demand

The prevalence of allergic conjunctivitis is increasing in conjunction with lifestyle and environmental changes. Exposure to air pollutants and various allergens has underscored the need for effective management and treatment options. The United States Environmental Protection Agency's recent report on pollutants accentuates the urgency of addressing such environmental factors that are impacting eye health globally.

Prevalence of Eye Disorders and Product Innovation Spearhead Growth

An increase in eye disorders, including allergic conjunctivitis, plays a significant role in the market's progression. Product innovation is a key trend where companies are introducing advanced treatment options. Notable product launches such as antihistamine eye drops have broadened the scope of effective treatments for allergy-induced eye discomforts.

Strategic Partnerships and Acquisitions Boost Market Presence

Strategically formed partnerships and acquisitions by key companies in the industry have strengthened market presence, offering comprehensive portfolios that address a full spectrum of ophthalmic needs. These business moves signify the potential for improved patient access to quality treatments across diverse regions.

North America Leads the Market Share

North America has been identified as the most significant contributor to market share in 2023. The report includes a thorough analysis of the various regions and countries that constitute the global market landscape, with a focus on the diverse range of treatment options available to patients. This noteworthy expansion of the allergy conjunctivitis market reflects a concentrated effort to meet the healthcare needs of those suffering from ocular allergies. With a growing emphasis on research and development, patients can anticipate more sophisticated and accessible treatment options in the near future.

A selection of companies mentioned in this report includes, but is not limited to:

  • Allergan PLC
  • AbbVie Inc.
  • Ajanta Pharma Limited
  • Akron Operating Company LLC
  • Alcon Inc.
  • Alembic Pharmaceuticals Ltd.
  • Atopix Therapeutics Ltd.
  • Auven Therapeutics Management LLLP
  • Bausch & Lomb
  • Cipla Ltd.
  • Grevis Pharmaceutical Private Limited
  • Indoco Remedies Ltd.
  • Jabs Biotech Pvt. Ltd.
  • JAWA Pharmaceuticals Pvt. Ltd.
  • Novartis AG
  • Ocular Therapeutix Inc.
  • Santen Pharmaceutical Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Laboratoires Thea SAS
  • Aciex Therapeutics Inc.
  • Bausch Health Companies Inc.
  • C.H. Boehringer Sohn AG & Co. KG
  • Eyevance Pharmaceuticals LLC
  • Johnson & Johnson Services Inc.
  • Mylan N.V.
  • Nicox S.A.
  • Omeros Corporation
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

For more information about this report visit https://www.researchandmarkets.com/r/qfu80p

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Copyright: 
Copyright Business Wire 2024